Clinical trials: Heart Failure (HF)
Heart Failure
Disease Management Platform for Heart Failure (DMP-HF)
AMAZE™ is a disease management platform (DMP) designed to educate patients about heart failure, help engage them in healthy behaviors and assist them in taking their medications as prescribed.
- Trial name
- DMP-HF (NCT04782973)
- Testing
- AMAZE (TM) Disease Management Platform
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
Management of Heart Failure in Italian Outpatients Clinics: Observational Study
OPTIMA-HF is an observational, cross-sectional, multicenter, real-life study conducted in two different clinical settings: HF outpatients' clinics of Italian University Hospitals and territorial Cardiology outpatients' services.
- Trial name
- OPTIMA-HF (NCT06287164)
- Testing
- Data collection
- Where
- Italy
- Volunteers
- 4,000 people
- Sponsor
- Federico II University
Heart Failure
iP2P Mentorship Program for Adolescent HF Patients
The iPeer2Peer (iP2P) program is an online peer support mentorship program that provides modelling and reinforcement by trained young adult peer mentors to adolescent mentees with the same condition.
- Trial name
- iP2P HF (NCT05709132)
- Testing
- iPeer2Peer Program
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- The Hospital for Sick Children
Heart Failure - NYHA II - IV
Peripheral Drivers of Heart Failure Progression - The Prospective PEDAL-HF Study
PEDAL-HF is a registry-based randomized prospective multicenter study. The investigators plan to include 1000 patients who were recently admitted with acute decompensated heart failure at five tertiary heart clinics in Germany.
- Trial name
- PEDAL-HF (NCT06656832)
- Testing
- Heart Failure network care
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University of Leipzig
Heart Failure With Reduced Ejection Fraction
PHARM Optimal-HF Pilot
The goal if this pilot randomized controlled trial is to determine the feasibility of conducting and guide the design of a definitive trial of a pharmacist-led, remotely-administered intervention to optimize medications for heart…
- Trial name
- NCT05623358
- Testing
- Pharmacist-led HFrEF medication optimization, Usual care
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University of British Columbia
Heart Failure
REDUCE LAP-HF TRIAL II
Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.
- Trial name
- NCT03088033
- Testing
- IASD System II implant, intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Where
- 91 sites in United States, Australia and 13 more
- Volunteers
- 608 people
- Sponsor
- Corvia Medical
Heart Failure
Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?
The purpose of this study is to determine if there is an interest to optimize HF (heart failure) management in patients over 80 years old.
- Trial name
- HF 80 (NCT01437371)
- Testing
- - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Clermont-Ferrand
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes…
- Trial name
- PROVIDE-HF (NCT03387163)
- Testing
- Sacubitril/Valsartan
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)
COMPASS-HF was a prospective, two-arm, randomized (1:1), multi-center, parallel controlled study. The purpose of the randomized study was to test the safety of an implantable hemodynamic monitor (IHM) and pressure sensor lead.
- Trial name
- NCT00643279
- Testing
- Chronicle Implantable Hemodynamic Monitor, Standard of Care
- Where
- 28 sites in United States
- Volunteers
- 277 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
China PEACE 5r-HF Study
This study will use a two-stage random sampling design to create a nationally representative sample of patients with heart failure (HF) in China.
- Trial name
- NCT02877914
- Testing
- Observational study
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- China National Center for Cardiovascular Diseases
Myocardial Infarction (MI), Heart Failure
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
Study objectives: To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF).
- Trial name
- TIMING-AHF (NCT07002164)
- Testing
- Immediate coronary angiography, Delayed coronary angiography
- Where
- 20 sites in South Korea
- Volunteers
- 780 people
- Sponsor
- Chonnam National University Hospital
Heart Failure With Normal Ejection Fraction
Interleukin-1 Blockade in HF With Preserved EF
Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure Standard treatment for heart failure, show less than ideal results in HFpEF Evidence of systemic inflammation is common in all forms of…
- Trial name
- D-HART2 (NCT02173548)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Heart Failure
ADHESION TO THERAPEUTIC STRATEGIES FOR OUTPATIENTS WITH HEART FAILURE - ADhesion-HF
The purpose of this study is to verify the impact of the educational intervention in the adhesion to therapeutic strategies for patients with heart failure.
- Trial name
- ADhesion-HF (NCT02230150)
- Testing
- Adhesion-HF
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Federal University of Bahia
HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction
Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare…
- Conditions
- HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction, Readmission Rates, Exercise Training
- Trial name
- EMPOWER-HFpEF (NCT07727096)
- Testing
- Exercise-Based Cardiac Rehabilitation, Guideline-Directed Medical Therapy
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure, Left Bundle-Branch Block
Conduction System Pacing Versus Biventricular Resynchronization in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the efficacy and safety of conduction system pacing versus biventricular pacing in patients with chronic heart failure with reduced ejection fraction and left bundle branch block.
- Conditions
- Heart Failure, Left Bundle-Branch Block, Cardiac Resynchronization, Conduction System Pacing
- Trial name
- PhysioSync-HF (NCT05572736)
- Testing
- Conduction system pacing, Biventricular pacing
- Where
- 14 sites in Brazil
- Volunteers
- 179 people
- Sponsor
- Hospital Moinhos de Vento
Heart Failure
Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure
The objective of this work is to investigate and then to sequence new biomarkers in the blood of patients with heart failure, and study their diagnostic, risk stratification and prognostic value.
- Trial name
- NCT03727828
- Testing
- Patients with heart failure
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Heart Failure, Chronic Kidney Diseases
Creating A Cardiorenal Multidisciplinary Team for Management HF and CKD Patients
Several drugs have been labeled as guideline-directed-medical therapies (GDMT) to improve overall health outcomes and slow the progression of disease in patients with heart failure (HF).
- Trial name
- NCT05531214
- Testing
- Multidisciplinary Care Coordination Team
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- George Washington University
Heart Failure
A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function
The purpose of this study is to determine the minimum effective dose of Istaroxime, in patients requiring hospitalization for deterioration of chronic heart failure and left ventricular systolic dysfunction.
- Trial name
- HORIZON-HF (NCT00616161)
- Testing
- Istaroxime
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.